Kanwar Meeta K, Sunku Ramya, Alruwaili Faisal, Mufti Mariam A, Raji Mukaila
Department of Internal Medicine, University of Texas Medical Branch, Galveston, USA.
Department of Internal Medicine-Division of Geriatrics & Palliative Medicine, University of Texas Medical Branch, Galveston, USA.
Cureus. 2022 Oct 28;14(10):e30812. doi: 10.7759/cureus.30812. eCollection 2022 Oct.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are approved to treat type 2 diabetes mellitus. The anti-inflammatory and anti-obesity properties of GLP-1 RAs as well as their moderating effects on multiple pathobiological pathways in asthma pathogenesis may decrease asthma exacerbations, improve quality of life, and decrease premature death among patients with asthma and co-morbid diabetes or obesity. The aim of this literature review is to discuss evidence from basic science, human studies, and clinical trials to support the preferential use of GLP-1 RAs in asthma patients with co-occurring diabetes and obesity. The preliminary data on the effect of GLP-1 RAs on asthma in patients with diabetes are promising and merit further trials and research studies.
胰高血糖素样肽-1受体激动剂（GLP-1 RAs）已被批准用于治疗2型糖尿病。GLP-1 RAs的抗炎和抗肥胖特性，以及它们对哮喘发病机制中多种病理生物学途径的调节作用，可能会减少哮喘发作，改善生活质量，并降低合并糖尿病或肥胖的哮喘患者的过早死亡风险。这篇文献综述的目的是讨论来自基础科学、人体研究和临床试验的证据，以支持在合并糖尿病和肥胖的哮喘患者中优先使用GLP-1 RAs。关于GLP-1 RAs对糖尿病患者哮喘影响的初步数据很有前景，值得进一步试验和研究。
